Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met5]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGFOGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.

Original languageEnglish (US)
Pages (from-to)579-587
Number of pages9
JournalExperimental Biology and Medicine
Volume238
Issue number5
DOIs
StatePublished - Aug 1 2013

Fingerprint

Ovarian Neoplasms
Opioid Analgesics
Intercellular Signaling Peptides and Proteins
Therapeutics
Cells
Naltrexone
Chemotherapy
Opioid Peptides
Narcotic Antagonists
Cyclin-Dependent Kinases
Enkephalins
methionine-enkephalin receptor
Cell Cycle
Necrosis
Up-Regulation
RNA
Tissue
Apoptosis
Drug Therapy
Proteins

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{853cdade38fb443487513a3abec36a15,
title = "Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer",
abstract = "The opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met5]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGFOGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.",
author = "Ian Zagon and Renee Donahue and Patricia McLaughlin",
year = "2013",
month = "8",
day = "1",
doi = "10.1177/1535370213488483",
language = "English (US)",
volume = "238",
pages = "579--587",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "5",

}

Targeting the opioid growth factor : Opioid growth factor receptor axis for treatment of human ovarian cancer. / Zagon, Ian; Donahue, Renee; McLaughlin, Patricia.

In: Experimental Biology and Medicine, Vol. 238, No. 5, 01.08.2013, p. 579-587.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting the opioid growth factor

T2 - Opioid growth factor receptor axis for treatment of human ovarian cancer

AU - Zagon, Ian

AU - Donahue, Renee

AU - McLaughlin, Patricia

PY - 2013/8/1

Y1 - 2013/8/1

N2 - The opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met5]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGFOGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.

AB - The opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis is a biological pathway that is present in human ovarian cancer cells and tissues. OGF, chemically termed [Met5]-enkephalin, is an endogenous opioid peptide that interfaces with OGFr to delay cells moving through the cell cycle by upregulation of cyclin-dependent inhibitory kinase pathways. OGF inhibitory activity is dose dependent, receptor mediated, reversible, protein and RNA dependent, but not related to apoptosis or necrosis. The OGFOGFr axis can be targeted for treatment of human ovarian cancer by (i) administration of exogenous OGF, (ii) genetic manipulation to over-express OGFr and (iii) use of low dosages of naltrexone, an opioid antagonist, which stimulates production of OGF and OGFr for subsequent interaction following blockade of the receptor. The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness. In summary, preclinical data support the transition of these novel therapies for treatment of human ovarian cancer from the bench to bedside to provide additional targets for treatment of this devastating disease.

UR - http://www.scopus.com/inward/record.url?scp=84881605592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881605592&partnerID=8YFLogxK

U2 - 10.1177/1535370213488483

DO - 10.1177/1535370213488483

M3 - Article

C2 - 23856908

AN - SCOPUS:84881605592

VL - 238

SP - 579

EP - 587

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 5

ER -